Axelia Oncology is a biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response.
Axelia Oncology is developing AXA-042, a potent selective, systemically delivered, TLR2/6 agonist for solid tumour indications.
AXA-042 development is based on vaccine adjuvant research from the laboratory of Professor David Jackson at the Peter Doherty Institute for Infection and Immunity, University of Melbourne.
